For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>GS-7340 (Tenofovir alafenamide) hemifumarate is an investigational oral prodrug of the HIV-1 nucleotide reverse transcriptase inhibitor Tenofovir (TFV).<br>Target: HIV-1, NRTIs[1]<br>InVitro: Tenofovir disoproxil fumarate (TDF) serves as a control for CatA-independent prodrug activation. Baseline antiviral activities (mean EC50±standard deviation) obtained in the absence of a protease inhibitors (PI) are determined from 6 independent donors for GS-7340 (EC50=5.3±1.2 nM) and TDF (EC50=2.8±1.1 nM) and are used to calculate fold change EC50s from four independent donors under conditions of PI pretreatment[1]. GS-7340 antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC50 varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC50s range from 0.1 to 12 nM, with a mean EC50 of 3.5 nM compared to a mean EC50 of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC50s are 1.8 nM for TAF and 6.4 nM for AZT[2].<br>InVivo: GS-7340 is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF) [1].</p>
| Catalog Number | I001502 |
| CAS Number | 1392275-56-7 |
| Molecular Formula | C21H29N6O5P.1/2 C4H4O4 |
| Purity | ≥95% |
| Target | HIV-1, NRTIs[1] |
| Solubility | DMSO |
| Storage | Store at RT |
| Reference | <p style=/line-height:25px/> <br>[2]. Callebaut C, et al. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. Antimicrob Agents Chemother. 2015 Oct;59(10):5909-16. </p> |
